课题基金 / 基金详情

项目摘要

项目成果

Raymond J Muller的其他基金

相似基金

相关文献

中文摘要
翻译
研究药学核心(RP)对MSKCC的翻译工作至关重要。核心支持 MSKCC将其科学发现从基于实验室的研究推进到以临床为基础的能力 概念验证测试。RP有三个主要组成部分:1)医药产品设施 (PPF)用于药物配方/稳定性和配伍问题;2)临床级生产(CGP)设施 用于大宗产品提纯和装瓶;以及3)药房调查药物服务(PIDS),该服务 支持临床前和临床使用的研究药物的准备和包装。RP工作人员 提供咨询、大宗产品分析和提纯、配方、包装、标签、稳定性/无菌 测试和配药。RP与调查产品核心携手工作,以准备 每个MSKCC的IND的化学、制造和控制科。通过RP,MSKCC可以 将内部想法推进到早期的人体试验中。由于RP的基础设施,MSKCC已经 能够将多种不同类型的药剂带入早期临床试验。其中包括传统的 小分子、放射性药物和疫苗。核心提供的服务支持 对过去一年来自5个项目和49个IRB方案的24名调查人员进行了研究。自上次审查以来, 《核心工作》为5个方案的25份出版物作出了贡献。例如,治疗性抗体 3F8是在MSKCC独家提纯、制造和瓶装的,构成了研究的骨干 神经母细胞瘤项目。它现在已经被证实是一种有效的治疗儿童 神经母细胞瘤。将碳水化合物和多肽结合在一起的大型复杂疫苗计划 复杂的KLH主干上的疫苗或与新佐剂混合的疫苗也依赖于 支持包括浆液性卵巢癌在内的癌症疫苗的临床测试的三方RP, 白血病、间皮瘤和肉瘤。
英文摘要
The Research Pharmacy Core (RP) is essential to the translational work of MSKCC. The Core supports the ability of MSKCC to advance its scientific discoveries from laboratory-based investigations to clinical-based Proof-of-Concept testing. The RP has three principal components: 1) The Pharmaceutical Product Facility (PPF) for drug formulation/stability and compatibility issues; 2) The Clinical Grade Production (CGP) Facility for bulk product purification and vialing; and 3) the Pharmacy Investigational Drug Service (PIDS) which supports the preparation and packaging of Investigational drugs for preclinical and clinical use. The RP staff provide consultation, bulk product analysis and purification, formulation, vialing, labeling, stability/sterility testing, and dispensing. The RP works hand-in-hand with the Investigational Products Core to prepare the Chemistry, Manufacturing, and Control Section for each of MSKCC's IND's. Through the RP, MSKCC can advance internal ideas into early human testing. Owing to the infrastructure of the RP, MSKCC has been able to bring multiple distinct types of pharmacologic agents into early clinical trials. These include traditional small molecules, radiopharmaceuticals, and vaccines. The services provided by the core have supported the research of 24 investigators from 5 Programs and 49 IRB protocols in the last year. Since the last review, the work of the Core has contributed to 25 publications from 5 Programs. For example, the therapeutic antibody 3F8 is purified, manufactured, and vialed exclusively at MSKCC and forms the backbone of the research program in neuroblastoma. It has now been validated as an effective treatment for children with neuroblastoma. The large and complex vaccine program, integrating both carbohydrate and peptide vaccines on complex KLH backbone or in mixtures with novel adjuvants is also dependent on the services of the tripartite RP to support the clinical testing of vaccines against cancers Including serous ovarian cancer, leukemia, mesothelioma, and sarcoma.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Research Pharmacy
  • 批准号:
    8933548
  • 项目类别:
  • 资助金额:
    $20.64万
  • 财政年份:
    2014
  • 负责人:
    Raymond J Muller
  • 依托单位:
Research Pharmacy
  • 批准号:
    10571817
  • 项目类别:
  • 资助金额:
    $21.38万
  • 财政年份:
    1997
  • 负责人:
    Raymond J Muller
  • 依托单位:
Research Pharmacy
  • 批准号:
    10319509
  • 项目类别:
  • 资助金额:
    $21.38万
  • 财政年份:
    1997
  • 负责人:
    Raymond J Muller
  • 依托单位:
Research Pharmacy
  • 批准号:
    10084829
  • 项目类别:
  • 资助金额:
    $21.38万
  • 财政年份:
    1997
  • 负责人:
    Raymond J Muller
  • 依托单位:
海外基金